A broad coalition of patient organizations today issued the following statement in response to cuts in staff, and research funding at federal agencies vital for American health. “Nearly every American ...
Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...
After weeks of disruption to scientific federal grants, the National Institutes of Health has fallen behind in funding ...
Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio ...
Claiming the cuts are illegal, attorneys general from 22 states, including Rhode Island, on Monday sued the Trump administration, the Department of Health and Human Services, and the National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results